Future Impact of GPRC5D-Targeted Therapies on RRMM Treatment

Opinion
Video

Panelists discuss how the evolution of GPRC5D-targeted therapies is expected to shape future treatment approaches for relapsed/refractory multiple myeloma in community practices by offering more personalized options and improving patient outcomes.

  • Panelists discuss how the evolution of GPRC5D-targeted therapies is expected to shape future treatment approaches for relapsed/refractory multiple myeloma in community practices by offering more personalized options and improving patient outcomes.
Recent Videos
Using the monitoring of symptoms and quality of life platform may provide a quick and efficient system for patients to submit outcome data.
Current FDA expectations may allow patients to return to their community physicians at 2 weeks after administration of anitocabtagene autoleucel.
Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
Two experts are featured in this series.
Two experts are featured in this series.
Two experts are featured in this series.
2 experts are featured in this series.
Related Content
The median OS among patients with triple-class–exposed relapsed/refractory multiple myeloma with or without EMD was 12.6 months vs 36.4 months.

EMD Associated With Poorer Outcomes in Previously Treated R/R Multiple Myeloma

Roman Fabbricatore
December 13th 2025
Article

The median OS among patients with triple-class–exposed relapsed/refractory multiple myeloma with or without EMD was 12.6 months vs 36.4 months.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Most CRS events were low grade with elranatamab plus daratumumab and lenalidomide without prophylactic tocilizumab in patients with multiple myeloma.

Tumor Burden Does Not Impact CRS Risk With Elranatamab Combo in Myeloma

Roman Fabbricatore
December 10th 2025
Article

Most CRS events were low grade with elranatamab plus daratumumab and lenalidomide without prophylactic tocilizumab in patients with multiple myeloma.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Belantamab mafodotin plus pomalidomide and dexamethasone led to a median PFS of 32.6 months in patients with relapsed/refractory multiple myeloma.

Belantamab Mafodotin Combo Sustains MRD Negativity/PFS in Multiple Myeloma

Tim Cortese
December 10th 2025
Article

Belantamab mafodotin plus pomalidomide and dexamethasone led to a median PFS of 32.6 months in patients with relapsed/refractory multiple myeloma.

Of the 4 patients with relapsed/refractory multiple myeloma who received KLN-1010, 1 complete response and 3 partial responses were achieved at varying levels of MRD sensitivity.

Investigational BCMA CAR-T Yields Responses/Safety in R/R Multiple Myeloma

Courtney Flaherty
December 9th 2025
Article

Of the 4 patients with relapsed/refractory multiple myeloma who received KLN-1010, 1 complete response and 3 partial responses were achieved at varying levels of MRD sensitivity.